Clinical Trial Update: A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

View source ↗

Summary

This ClinicalTrials.gov update reports results from a completed Danish study of HR+/HER2- metastatic breast cancer patients treated with palbociclib in combinat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Palbociclib (Ibrance) (palbociclib)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Status: COMPLETED | Results posted: 2025-06-29